SPY397.37+3.48 0.88%
DIA321.28+1.89 0.59%
IXIC11,434.74+170.29 1.51%

BRIEF-Opiant Pharmaceuticals And Hikma Announce Exclusive $225 Million Commercialisation And License Agreement For Opnt003, Nasal Nalmefene, In Europe And The Uk

reuters.com · 04/29/2022 10:18
BRIEF-Opiant Pharmaceuticals And Hikma Announce Exclusive $225 Million Commercialisation And License Agreement For Opnt003, Nasal Nalmefene, In Europe And The Uk

- Hikma Pharmaceuticals PLC HKMPY:

  • OPIANT PHARMACEUTICALS UK - CO ALSO ELIGIBLE FOR SINGLE DIGIT TIERED ROYALTIES ON EU AND UK SALES OF OPNT003, AS PART OF DEAL

  • OPIANT PHARMACEUTICALS AND HIKMA ANNOUNCE EXCLUSIVE $225 MILLION COMMERCIALISATION AND LICENSE AGREEMENT FOR OPNT003, NASAL NALMEFENE, IN EUROPE AND THE UK

  • OPIANT PHARMACEUTICALS UK - AS PART OF DEAL, CO WILL RECEIVE $175 MILLION UPFRONT ALONG WITH $50 MILLION IN MILESTONES UPON LAUNCH

  • OPIANT PHARMA UK - IN DEAL, CO IS RESPONSIBLE FOR DEVELOPMENT & FILLING OF OPNT003 & WILL SUPPLY FINISHED COMMERCIAL PRODUCTS FOR EU & UK MARKETS

  • OPIANT PHARMACEUTICALS UK - IN DEAL, HIKMA RESPONSIBLE FOR REGISTERING OPNT003 WITH EUROPEAN MEDICINES AGENCY

  • OPIANT PHARMACEUTICALS UK - HIKMA WILL HAVE EXCLUSIVE RIGHTS TO COMMERCIALISE THE PRODUCT, OPNT003, IN THE EU AND UK, AS PART OF DEAL

Source text for Eikon: [ID:]

Further company coverage: HKMPY


((Reuters.Briefs@thomsonreuters.com;;))